New Killer Virus Trial Raises Alarming Questions

(DailyChive.com) – Oxford scientists launch the world’s first Phase II trial for a Nipah virus vaccine against a bat-borne killer with up to 75% fatality, raising questions about global health priorities under President Trump’s America First agenda.

Story Highlights

University of Oxford initiates Phase II trials in Bangladesh for ChAdOx1 NipahB vaccine, enrolling 306 participants after safe Phase I results.
Nipah virus, endemic in Bangladesh with near-annual outbreaks, has killed over 400 since 1998 with fatality rates of 40-75% and no approved treatments.
Funded by CEPI with $7.3 million, the trial partners with local researchers to test efficacy in high-risk areas.
Progress builds on viral vector technology from Oxford’s COVID vaccine, advancing pandemic preparedness without U.S. taxpayer burden.

Nipah Virus Threat Emerges

Nipah virus first struck in 1998-1999 among Malaysian pig farmers, killing 105 of 265 humans and forcing massive pig culls. Fruit bats serve as natural reservoirs across Asia, Africa, and beyond. The pathogen causes acute encephalitis and respiratory failure. Outbreaks shifted to Bangladesh and India from 2001, linked to contaminated date palm sap, with near-annual incidents and confirmed fatalities in 2025. No vaccines or treatments exist, driving WHO priority status due to person-to-person spread potential.

Phase II Trials Launch in Bangladesh

Early December 2025 marked the start of the world’s first Phase II clinical trial for ChAdOx1 NipahB in Bangladesh. The University of Oxford’s Pandemic Sciences Institute and Vaccine Group lead development. Trials enroll 306 healthy adults aged 18-55 at the International Centre for Diarrhoeal Disease Research (icddr,b). This follows Phase I in Oxford, where 51 participants completed one-year follow-up safely, with results imminent. Professor Dame Sarah Gilbert calls it a testament to international collaboration.

Key Developers and Funding

Professor Brian Angus, Chief Investigator, oversees trials to ensure effectiveness in outbreak zones and equitable access. CEPI provides over $7.3 million, with Dr. Kent Kester praising it as the most advanced Nipah candidate and a step for countermeasures. The viral vector platform echoes Oxford-AstraZeneca’s COVID vaccine technology. Local icddr,b expertise addresses endemic risks, countering North-South vaccine access imbalances. This model prioritizes field testing in high-risk regions over lab isolation.

Separate preclinical advances include a DS90-m102.4 antibody from alpaca nanobodies and monoclonals. It showed 100% protection in hamsters against Nipah and related Hendra strains, per a recent Nature study. Experts like Balasubramaniam at Monash University hail it as a revolution, though human trials remain pending.

Potential Impacts and Cautions

Phase II success could fast-track Phase III, equipping outbreak responses and cutting costs like Malaysia’s 1999 culls. Long-term, a vaccine reduces pandemic risks from paramyxoviruses, benefiting pig farmers, healthcare workers, and bat-endemic communities in Bangladesh, India, and globally. It validates investments in priority pathogens post-COVID. Conservative Americans welcome private innovation in global health that avoids wasteful federal overreach, focusing resources on domestic priorities like border security and economic strength under President Trump.

Major breakthrough in vaccine development for deadly virus with 75% fatality rate https://t.co/LAFN9xfA7D pic.twitter.com/CMr73y9ACa

— The Independent (@Independent) December 12, 2025

Short-term, antibody progress offers interim options while trials advance. Uncertainties persist: fatality rates vary 40-75%, Phase I data awaits full release, and no human treatments exist yet. Ongoing 2025 Bangladesh deaths underscore urgency, but success hinges on endemic efficacy.